STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co Stock Price, News & Analysis

BMY NYSE

Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.

Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical leader developing innovative therapies in oncology, cardiovascular diseases, and immunology. This dedicated news hub provides investors and healthcare professionals with direct access to BMY's latest developments, including FDA approvals, clinical trial results, and strategic partnerships.

Track critical updates through curated press releases covering drug development milestones, financial earnings reports, and research collaborations. Our aggregation ensures you never miss regulatory filings, product launch announcements, or patent developments impacting BMY's market position.

Discover timely information on therapeutic advancements in immuno-oncology and hematology, plus insights into global healthcare trends affecting pharmaceutical operations. Bookmark this page for streamlined monitoring of BMY's scientific innovations and corporate announcements essential for informed analysis.

News

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) announced FDA approval of significant label updates for its CAR T cell therapies Breyanzi and Abecma. The updates include reduced patient monitoring requirements and removal of REMS programs, reflecting increased confidence in the therapies' safety profiles.

Key changes include reduction of driving restrictions from 8 to 2 weeks and requirement to stay near healthcare facilities reduced from 4 to 2 weeks post-treatment. Currently, only 2 in 10 eligible patients receive cell therapy treatment due to logistical and geographic barriers.

BMS will work with over 150 treatment centers to implement these changes and expand into community cancer centers nationwide, aiming to increase accessibility to these potentially life-saving treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News

Bristol Myers Squibb Announces Dividend

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) has declared its latest quarterly dividend payments. The company will pay a quarterly dividend of $0.62 per share on its common stock, payable on August 1, 2025, to stockholders of record as of July 3, 2025. Additionally, BMY announced a quarterly dividend of $0.50 per share on its $2.00 convertible preferred stock, which will be paid on September 2, 2025, to stockholders of record as of August 5, 2025. This dividend announcement reflects BMY's commitment to providing regular returns to its shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
dividends
-
News

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

Rhea-AI Summary
Bristol Myers Squibb announced groundbreaking results from the TRANSCEND FL trial's marginal zone lymphoma cohort evaluating Breyanzi (lisocabtagene maraleucel). The study showed remarkable efficacy with 95.5% overall response rate and 62.1% complete response rate in relapsed/refractory MZL patients. At 24 months, 88.6% maintained response duration, with 85.7% progression-free survival and 90.4% overall survival. Safety profile remained consistent, with manageable cytokine release syndrome (76% any grade, 4% Grade 3) and neurologic events (33% any grade, 4% Grade 3). This marks Breyanzi's success in a fifth cancer type, the most among CD19-directed CAR T therapies. The therapy demonstrated particular promise for MZL patients, who typically face a 3-5 year median survival after multiple relapses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
News

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) presented promising data from its targeted protein degradation platform at EHA 2025, featuring clinical findings on CELMoD agents and BCL6 ligand-directed degrader. Key highlights include mezigdomide showing 75-85% overall response rates in multiple myeloma, iberdomide demonstrating 88.9% response rate in newly diagnosed multiple myeloma, and golcadomide achieving up to 94% response rate in follicular lymphoma when combined with rituximab. The first-in-human study of BCL6 LDD (BMS-986458) showed an 81% overall response rate in non-Hodgkin lymphoma. Multiple Phase 3 trials are ongoing with data readouts expected between 2025-2030. The company's protein degraders are designed to target specific disease-driving proteins and potentially enhance existing therapies' efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
News

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) has scheduled its second quarter 2025 financial results announcement for Thursday, July 31, 2025. The company will host a conference call and live webcast at 8:00 a.m. ET, where executives will discuss the quarterly performance with the investment community. Investors and the public can access the webcast at investor.bms.com, where related materials will be available before the call. A replay will be accessible approximately three hours after the call concludes at the same website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
conferences earnings
-
News

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced positive Phase 3 POETYK PsA-1 trial results for Sotyktu in adults with psoriatic arthritis. The trial met its primary endpoint with 54.2% of Sotyktu-treated patients achieving ACR20 response versus 34.1% for placebo at Week 16 (p<0.0001). The drug showed significant improvements across multiple measures including joint symptoms, skin conditions, and quality of life. Key secondary endpoints were met, including PASI 75 response and other clinical measures. New data from POETYK PsA-2 trial demonstrated maintained efficacy through Week 52, with 62.2% of continuous Sotyktu patients achieving ACR20 response. The safety profile remained consistent with previous trials, with upper respiratory tract infection being the most common adverse event (5.1% vs 3.0% for placebo).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
clinical trial
News

Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference scheduled for June 11, 2025. The company will engage in a fireside chat starting at 10:00 a.m. ET. Both investors and the general public can access the session through the company's investor relations website at http://investor.bms.com. An archived recording of the session will be made available after its conclusion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
conferences
-
News

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) has received European Commission approval for Opdivo SC, a new subcutaneous formulation of its PD-1 inhibitor nivolumab, across multiple solid tumor indications. This marks Opdivo as the first and only PD-1 inhibitor approved for subcutaneous use in the EU. The approval is based on the Phase 3 CheckMate -67T trial, which demonstrated noninferiority in pharmacokinetics and consistent efficacy compared to the intravenous formulation. The new formulation reduces administration time to just 3-5 minutes, compared to traditional IV infusion. The approval covers use as monotherapy, maintenance therapy following IV nivolumab plus Yervoy combination, or in combination with chemotherapy or cabozantinib. The safety profile remained consistent with the IV formulation, with serious adverse reactions occurring in 28% of patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
News

Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) will present data from over 80 studies across 20+ cancer types at the 2025 ASCO Annual Meeting (May 30-June 3, Chicago). Key highlights include: • Head & Neck Cancer: Phase 3 NIVOPOSTOP study results of adjuvant nivolumab with radio-chemotherapy for high-risk HNSCC • Lung Cancer: 5-year survival analysis from CheckMate-816 studying Opdivo with chemotherapy for NSCLC • Esophageal Cancer: 5-year OS results from CheckMate-577 evaluating adjuvant Opdivo • Blood Disorders: First OS results from COMMANDS study comparing Reblozyl vs. epoetin alfa in MDS patients • Pipeline Updates: Data on BMS-986504 for MTAP-deleted tumors, KRAZATI for KRAS-mutated NSCLC, and iza-bren for lung cancers • Cell Therapy: Analysis of Breyanzi treatment in over 1,500 patients and arlo-cel data in multiple myeloma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
conferences
News

Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference

Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) has announced its participation in the Bernstein 41st Annual Strategic Decisions Conference scheduled for Wednesday, May 28, 2025. The company will engage in a fireside chat starting at 3:30 p.m. ET. Both investors and the general public can access the session through the company's investor relations website at investor.bms.com. An archived version of the session will be made available after its conclusion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
conferences

FAQ

What is the current stock price of Bristol-Myers Squibb Co (BMY)?

The current stock price of Bristol-Myers Squibb Co (BMY) is $46.43 as of July 15, 2025.

What is the market cap of Bristol-Myers Squibb Co (BMY)?

The market cap of Bristol-Myers Squibb Co (BMY) is approximately 94.6B.
Stock BMY logo
Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

#140 Ranked by Market Cap
#604 Ranked by Dividends

BMY Stock Data

94.61B
2.03B
0.1%
80.86%
1.51%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON